Citations

Clear

361 citation(s) found for "Bauer, M".

New Paradigms for Thoracic Outlet Compression and Thoracic Outlet Syndrome, with or without Complications or Sequelae: A Trans-Continental and Trans-Disciplinary Opinion Paper
Abraham, Pierre , Wennberg, Paul W. , Bauer, Pascal , Gu, Yongquan, Ouédraogo, Nafi, Guo, Lianrui , Tew, Garry A. , Martini, Romeo , Henni, Samir , Gu, Yongquan , Mazzolai, Lucia

Mayo Clinic

Journal of Vascular Diseases | November 2, 2023 | Volume: 2 | Issue: 4 | Pages: 413-418

10.3390/jvd2040032 Get It

The anatomy of the human shoulder predisposes the neurovascular bundle to compression at different levels of the thoracic outlet during abduction of the arm. There are four possible levels of compression at the thoracic outlet pathway: at the costo-clavicular angle, the inter-scalenic angle, under the pectoralis minor muscle or at the level of the humeral head. The positional thoracic outlet compression (TOC) often remains completely asymptomatic. When symptomatic, compressions are collectively referred to as thoracic outlet syndrome (TOS) and may require surgery if physical therapy fails to improve symptoms. The “thoracic outlet compression with complications or sequelae” (the acronym of which is “TOC-CS”, which can be simplified as “TOX”) will almost invariably lead to surgery to release the compression, and other possible treatment targeting the complications as required. There is a continuum between TOC, TOS and TOX, which are simply different clinical stages of the same mechanical issue, just like the Rutherford grades represent different stages of lower extremity arterial disease. We believe that discriminating between TOC, TOS and TOX clarifies clinical definitions and their respective treatment options. TOC is to be considered as a physiological positional phenomenon, TOS requires medical or surgical treatment and surgery should be considered as a primary option in TOX.
Comment on “Hydrocortisone versus vasopressin for the management of adult patients with septic shock refractory to norepinephrine: A multicenter retrospective study”
Wieruszewski, Patrick M. , Bauer, Seth R. , Bauer, Seth R , Wieruszewski, Patrick M

Mayo Clinic

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy | October 12, 2023 | Volume: 43 | Issue: 10 | Pages: 1094-1094

10.1002/phar.2870 | PMID 37823712 Get It

Complementary and alternative medicine for long COVID: a systematic review of randomized controlled trials
Yang, Juan , Lim, Kia Hui , Lim, Kia Teng , Woods, Jeffrey , Mohabbat, Arya B. , Wahner‐Roedler, Dietlind L. , Bauer, Brent A. , Woods, Jeffrey T., Ganesh, Ravindra

Mayo Clinic

Therapeutic Advances in Chronic Disease | October 12, 2023 | Volume: 14 | Issue: No issue available | Pages: No page available

10.1177/20406223231204727 | PMID 37841213 Get It

Background: Complementary and alternative medicine (CAM) interventions are growing in popularity as possible treatments for long COVID symptoms. However, comprehensive analysis of current evidence in this setting is still lacking. Objective: This study aims to review existing published studies on the use of CAM interventions for patients experiencing long COVID through a systematic review. Design: Systematic review of randomized controlled trials (RCTs). Methods: A comprehensive electronic literature search was performed in multiple databases and clinical trial registries from September 2019 to January 2023. RCTs evaluating efficacy and safety of CAM for long COVID were included. Methodological quality of each included trial was appraised with the Cochrane ‘risk of bias’ tool. A qualitative analysis was conducted due to heterogeneity of included studies. Results: A total of 14 RCTs with 1195 participants were included in this review. Study findings demonstrated that CAM interventions could benefit patients with long COVID, especially those suffering from neuropsychiatric disorders, olfactory dysfunction, cognitive impairment, fatigue, breathlessness, and mild-to-moderate lung fibrosis. The main interventions reported were self-administered transcutaneous auricular vagus nerve stimulation, neuro-meditation, dietary supplements, olfactory training, aromatherapy, inspiratory muscle training, concurrent training, and an online breathing and well-being program. Conclusion: CAM interventions may be effective, safe, and acceptable to patients with symptoms of long COVID. However, the findings from this systematic review should be interpreted with caution due to various methodological limitations. More rigorous trials focused on CAM for long COVID are warranted in the future.
Lithium Response in Bipolar Disorder is Associated with Focal Adhesion and PI3K-Akt Networks: A Multi-omics Replication Study
Ou, Anna , Adli, Mazda , Akiyama, Kazufumi , Akula, Nirmala , Amare, Azmeraw T. , Ardau, Raffaella , Arias, Bárbara , Aubry, Jean‐Michel , Bauer, Michael , Benabarre, Antonio , Bengesser, Susanne , Abesh, Bhattacharjee, Bui, Elise T. , Cervantes, Pablo , Chillotti, Caterina , Cichon, Sven , Clark, Scott R. , Cousins, David A. , Cruceanu, Cristiana , Degenhardt, Franziska , Ferensztajn‐Rochowiak, Ewa , Forstner, Andreas J. , Frisén, Louise , Frye, Mark A. , Gard, Sébastien, Grof, Paul , Gruber, Oliver , Kahn, Jean‐Pierre, Kassem, Layla, Kittel‐Schneider, Sarah , Dalkner, Nina , Laje, Gonzalo, Landén, Mikael , Lavebratt, Catharina , Leckband, Susan G. , López‐Jaramillo, Carlos , Maj, Mario , Mattheisen, Manuel , McCarthy, Michael J. , Mitjans, Marina , Mondimore, Francis M. , Nöthen, Markus M. , Ösby, Urban, Perlis, Roy H. , Pfennig, Andrea , Potash, James B. , Schalling, Martin , Schubert, Klaus Oliver , Schweizer, Barbara , Severino, Giovanni , Shekhtman, Tatyana , Shilling, Paul D. , Shimoda, Kazutaka , Simhandl, Christian , Slaney, Claire , Stamm, Thomas , Tighe, Sarah K., Volkert, Julia, Witt, Stephanie H. , Zandi, Peter P. , Zompo, Maria Del , Ou, Anna , Alda, Martin , Amare, Azmeraw , Arias, Bárbara , Bauer, M , Baune, Bernhard , Biernacka, Joanna , Chen, Hsi-Chung , Clark, Scott , Cruceanu, Cristiana , Czerski, Piotr , DePaulo, J Raymond , Etain, B , Forstner, Andreas J , Frye, Mark , Fullerton, Janice M , Garnham, Julie , Grigoroiu-Serbanescu, Maria , Hashimoto, Ryota , Hauser, Joanna , Heilbronner, Urs , Hou, Liping , Jamain, Stéphane , Kato, Tadafumi , Kuo, Po-Hsiu , Kusumi, Ichiro , Landén, Mikael , Lavebratt, Catharina , Leboyer, Marion , Marie-Claire, Cynthia , McMahon, Francis , Mitchell, Philip B , Mitjans, Marina , Nievergelt, Caroline M , Nöthen, Markus M , Novak, Tomas , Ozaki, Norio , Papiol, Sergi , Reif, Andreas , Reininghaus, Eva , Rietschel, Marcella , Rouleau, Guy Armand , Rybakowski, Janusz K , Schalling, Martin , Schofield, Peter R , Schubert, Klaus Oliver , Schulze, Thomas , Severino, Giovanni , Shilling, Paul , Shimoda, Kazutaka , Squassina, Alessio , Turecki, Gustavo , Vieta, E , Witt, Stephanie H , Wray, Naomi , Del Zompo, Maria , Cichon, Sven , López-Jaramillo, Carlos , Kittel-Schneider, Sarah , McCarthy, Michael , Perlis, Roy H , Kelsoe, John R , Jiang, Qingfei , Alda, Martin , Backlund, Lena , Banzato, Cláudio E. M. , Bellivier, Frank , Biernacka, Joanna M. , Chen, Guo‐Bo , Chen, Hsi‐Chung , Colom, Francesc , Czerski, Piotr M. , Dantas, Clarissa de Rosalmeida , Dayer, Alexandre G. , Étain, Bruno , Falkai, Peter , Fellendorf, Frederike T. , Fullerton, Janice M. , Goes, Fernando , Grigoroiu‐Serbânescu, Maria , Hashimoto, Ryota , Heilbronner, Urs , Herms, Stefan , Hoffmann, Per , Hofmann, Andrea , Jamain, Stéphane , Jiménez, Esther , Kato, Tadafumi , König, Barbara , Kuo, Po‐Hsiu , Dalkner, Nina , Leboyer, Marion , MacQUEEN, GLENDA M. , Manchia, Mirko , Martinsson, Lina , McElroy, Susan L. , McMahon, Francis J. , Monteleone, Palmiero , Novák, Tomáš , Ozaki, Norio , Papiol, Sergi , Reich‐Erkelenz, Daniela , Reif, Andreas , Schofield, Peter R. , Seemüller, Florian , Squassina, Alessio , Stopková, Pavla , Tortorella, Alfonso , Turecki, Gustavo , Vieta, Eduard , Wright, Adam, Young, Trevor

Mayo Clinic

No container title available | October 3, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3258813/v1 | PMID 37886563 Get It

Abstract Lithium is the gold standard treatment for bipolar disorder (BD). However, its mechanism of action is incompletely understood, and prediction of treatment outcomes is limited. In our previous multi-omics study of the Pharmacogenomics of Bipolar Disorder (PGBD) sample combining transcriptomic and genomic data, we found that focal adhesion, the extracellular matrix (ECM), and PI3K-Akt signaling networks were associated with response to lithium. In this study, we replicated the results of our previous study using network propagation methods in a genome-wide association study of an independent sample of 2,039 patients from the International Consortium on Lithium Genetics (ConLiGen) study. We identified functional enrichment in focal adhesion and PI3K-Akt pathways, but we did not find an association with the ECM pathway. Our results suggest that deficits in the neuronal growth cone and PI3K-Akt signaling, but not in ECM proteins, may influence response to lithium in BD.
PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer
Ali, Lestat R. , Lenehan, Patrick J. , Cardot‐Ruffino, Victoire , Costa, Andressa Dias , Bauer, Todd W. , Nowak, Jonathan A. , Wolpin, Brian M. , Abrams, Thomas A. , Patel, Anuj , Clancy, Thomas E. , Wang, Jiping , Mancias, Joseph D. , Stucky, Chee‐Chee , Bekaii‐Saab, Tanios , Merchant, Nipun B. , Slingluff, Craig L. , Rahma, Osama E. , Dougan, Stephanie K. , Dias Costa, Andressa , Katz, Matthew H G , Bauer, Todd W , Nowak, Jonathan A , Wolpin, Brian M , Abrams, Thomas A , Patel, Anuj , Clancy, Thomas E , Wang, Jiping , Mancias, Joseph D , Reilley, Matthew J , Stucky, Chee-Chee H , Bekaii-Saab, Tanios S , Elias, Rawad , Merchant, Nipun , Slingluff, Craig L , Rahma, Osama E , Dougan, Stephanie K , Lenehan, Patrick J , Katz, Matthew H. G. , Reilley, Matthew J. , Elias, Rawad

Mayo Clinic

Clinical Cancer Research | September 21, 2023 | Volume: 30 | Issue: 3 | Pages: 542-553

10.1158/1078-0432.ccr-23-1444 | PMID 37733830 Get It

Abstract Purpose: Pancreatic ductal adenocarcinoma (PDAC) trials have evaluated CTLA-4 and/or PD-(L)1 blockade in patients with advanced disease in which bulky tumor burden and limited time to develop antitumor T cells may have contributed to poor clinical efficacy. Here, we evaluated peripheral blood and tumor T cells from patients with PDAC receiving neoadjuvant chemoradiation plus anti–PD-1 (pembrolizumab) versus chemoradiation alone. We analyzed whether PD-1 blockade successfully reactivated T cells in the blood and/or tumor to determine whether lack of clinical benefit could be explained by lack of reactivated T cells versus other factors. Experimental Design: We used single-cell transcriptional profiling and TCR clonotype tracking to identify TCR clonotypes from blood that match clonotypes in the tumor. Results: PD-1 blockade increases the flux of TCR clonotypes entering cell cycle and induces an IFNγ signature like that seen in patients with other GI malignancies who respond to PD-1 blockade. However, these reactivated T cells have a robust signature of NF-κB signaling not seen in cases of PD-1 antibody response. Among paired samples between blood and tumor, several of the newly cycling clonotypes matched activated T-cell clonotypes observed in the tumor. Conclusions: Cytotoxic T cells in the blood of patients with PDAC remain sensitive to reinvigoration by PD-1 blockade, and some have tumor-recognizing potential. Although these T cells proliferate and have a signature of IFN exposure, they also upregulate NF-κB signaling, which potentially counteracts the beneficial effects of anti–PD-1 reinvigoration and marks these T cells as non-productive contributors to antitumor immunity. See related commentary by Lander and DeNardo, p. 474
Global Cardio Oncology Registry (G-COR): Registry Design, Primary Objectives, and Future Perspectives of a Multicenter Global Initiative
Teske, Arco J. , Moudgil, Rohit , López‐Fernández, Teresa , Barac, Ana , Brown, Sherry, Deswal, Anita , Neilan, Tomas G. , Ganatra, Sarju , Qadir, Husam Abdel, Menon, Venu , Sverdlov, Aaron L. , Cheng, Richard K. , Makhoul, Silvia , Ghosh, Arjun K. , Szmit, Sebastian , Addison, Daniel , Zhang, Lili , Herrmann, Joerg , Chong, Jun Hua , Agarwala, Vivek , Iakobishvili, Zaza , Guerrero, Patricia A., Leja, Monika, Guha, Avirup , Okwuosa, Tochukwu, Silva, Carolina Carvalho, DeCara, Jeanne M. , Bauer, Brenton , Lenneman, Carrie , Sadler, Diego , Zaha, Vlad G , Addison, Daniel , Agarwala, Vivek , Iakobishvili, Zaza , Yang, Eric , Akhter, Nausheen , Guha, Avirup , Okwuosa, Tochukwu M , Collier, Patrick , DeCara, Jeanne , Bauer, Brenton , Sadler, Diego , Deswal, Anita M , Barac, Ana , López-Fernández, Teresa , Sverdlov, Aaron L , Cheng, Richard , Brown, Sherry‐Ann , Collier, Patrick

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | September 13, 2023 | Volume: 16 | Issue: 10 | Pages: No page available

10.1161/circoutcomes.123.009905 | PMID 37702048 Get It

BACKGROUND: Global collaboration in cardio-oncology is needed to understand the prevalence of cancer therapy-related cardiovascular toxicity in different risk groups, practice settings, and geographic locations. There are limited data on the socioeconomic and racial/ethnic disparities that may impact access to care and outcomes. To address these gaps, we established the Global Cardio-Oncology Registry, a multinational, multicenter prospective registry. METHODS: We assembled cardiologists and oncologists from academic and community settings to collaborate in the first Global Cardio-Oncology Registry. Subsequently, a survey for site resources, demographics, and intention to participate was conducted. We designed an online data platform to facilitate this global initiative. RESULTS: A total of 119 sites responded to an online questionnaire on their practices and main goals of the registry: 49 US sites from 23 states and 70 international sites from 5 continents indicated a willingness to participate in the Global Cardio-Oncology Registry. Sites were more commonly led by cardiologists (85/119; 72%) and were more often university/teaching (81/119; 68%) than community based (38/119; 32%). The average number of cardio-oncology patients treated per month was 80 per site. The top 3 Global Cardio-Oncology Registry priorities in cardio-oncology care were breast cancer, hematologic malignancies, and patients treated with immune checkpoint inhibitors. Executive and scientific committees and specific committees were established. A pilot phase for breast cancer using Research Electronic Data Capture Cloud platform recently started patient enrollment. CONCLUSIONS: We present the structure for a global collaboration. Information derived from the Global Cardio-Oncology Registry will help understand the risk factors impacting cancer therapy-related cardiovascular toxicity in different geographic locations and therefore contribute to reduce access gaps in cardio-oncology care. Risk calculators will be prospectively derived and validated.
Satisfaction and Feasibility Evaluation of an Electronic Massager—Expert Manipulative Massage Automation (EMMA): A Pilot Study
Yang, Juan , Croghan, Ivana T. , Fokken, Shawn C. , Johnson, Devan E., Calva, Jason J., Do, Alexander , Mueller, Michael , Bauer, Brent A. , Chon, Tony Y.

Mayo Clinic

Journal of Primary Care & Community Health | September 12, 2023 | Volume: 14 | Issue: No issue available | Pages: No page available

10.1177/21501319231199010 | PMID 37698255 Get It

Background: Electronic massagers have gained popularity for their non-invasive and cost-effective approach to healthcare. However, existing electronic massagers require manual manipulation, leading to inconsistency. Objective: To investigate the feasibility and acceptability of the Electronic Massager—Expert Manipulative Massage Automation (EMMA) among the American population. Methods: A single-arm pilot study was conducted at Mayo Clinic Rochester campus. Participants received massage therapy with the EMMA treatment model and completed a demographics and Satisfaction Survey Questionnaire. Data were collected using REDCap, and statistical analysis was performed. Results: Twenty healthy volunteers (13 women, 7 men; median age, 47 years) participated and completed the intervention within 2 weeks. No adverse events were reported. Overall, the acceptability and satisfaction of massage utilizing EMMA were high, with all participants finding the study worthwhile, willing to participate again, and willing to recommend the study to others. Regarding the overall experience, 65.0% reported a better-than-expected experience. Responses to open-ended post-treatment questions showed that most participants enjoyed the warmth (35%), pressure (25%), and relaxation (20%) provided by EMMA, with the majority suggesting no changes or improvements were needed. However, some participants expressed a desire for an expanded massage area (20%). Conclusions: This study suggests that the EMMA massager has high acceptability and satisfaction among healthy volunteers, thus demonstrating its feasibility. However, further research is needed to optimize EMMA and assess its clinical effectiveness.
Changes in Doppler‐Derived Kidney Venous Flow and Adverse Cardiorenal Outcomes in Patients With Heart Failure
Husain‐Syed, Faeq , Viehman, Jason K., Vaughan, Lisa E. , Bauer, Pascal , Gall, Henning , Tello, Khodr , Richter, Manuel J. , Yogeswaran, Athiththan , Romero‐González, Gregorio , Rosner, Mitchell H. , Aßmus, Birgit , Seeger, Werner , Birk, Horst‐Walter, Singam, N Sarma V , Vaughan, Lisa , Gall, Henning , Tello, Khodr , Yogeswaran, Athiththan , Romero-González, Gregorio , Ghofrani, Hossein Ardeschir , Seeger, Werner , Kashani, Kianoush B , Husain-Syed, Faeq , Singam, Narayana Sarma V. , Ronco, Claudio , Ghofrani, Hossein Ardeschir , Kashani, Kianoush

Mayo Clinic

Journal of the American Heart Association | August 14, 2023 | Volume: 12 | Issue: 16 | Pages: No page available

10.1161/jaha.123.030145 | PMID 37577933 Get It

Background The impact of changes in Doppler‐derived kidney venous flow in heart failure (HF) is not well studied. We aimed to investigate the association of Doppler‐derived kidney venous stasis index (KVSI) and intrakidney venous‐flow (IKVF) patterns with adverse cardiorenal outcomes in patients with HF. Methods and Results In this observational cohort study, consecutive inpatients with HF referred to a nephrologist because of a history of diuretic resistance and abnormal kidney function (n=216) underwent spectral kidney assessments after admission (Doppler 1) and 25 to 35 days later (Doppler 2) to identify IKVF patterns (continuous/pulsatile/biphasic/monophasic) and KVSI levels. Cox proportional hazard regression models were used to evaluate the associations between KVSI/IKVF patterns at Doppler 1 as well as changes from Doppler 1 to Doppler 2 and risk of cardiorenal events up to 18 months after admission. Worsening HF or death occurred in 126 patients. Both baseline KVSI (hazard ratio [HR], 1.49 [95% CI, 1.37–1.61] per 0.1‐unit increase) and baseline IKVF pattern (HR, 2.47 [95% CI, 2.01–3.04] per 1 pattern severity increase) were significantly associated with worsening HF/death. Increases in both KVSI and IKVF pattern severity from Doppler 1 to 2 were also associated with an increased risk of worsening HF/death (HR, 3.00 [95% CI, 2.08–4.32] per 0.1‐unit increase change; and HR, 6.73 [95% CI, 3.27–13.86] per 1 pattern increase in severity change, respectively). Similar results were observed for kidney outcomes. Conclusions Baseline kidney venous flow predicted adverse cardiorenal events, and inclusion of serial kidney venous flow in cardiorenal risk stratification could facilitate clinical decision‐making for patients with HF. Registration URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03039959.
The use of complementary and alternative medicine for the treatment of gastrointestinal symptoms in Long COVID: a systematic review
Gawey, Brent J. , Yang, Juan , Bauer, Brent A. , Song, Joanne, Gawey, Brent , Bauer, Brent, Wang, Xiao‐Jing

Mayo Clinic

Therapeutic Advances in Chronic Disease | August 11, 2023 | Volume: 14 | Issue: No issue available | Pages: No page available

10.1177/20406223231190548 | PMID 37577106 Get It

Background: Most people with coronavirus disease 2019 (COVID-19) experience resolution of symptoms within days to weeks following initial infection. In a subset of individuals, symptoms persist longer than 4 weeks, known as ‘Long COVID’. Many gastrointestinal (GI) symptoms persist as part of this syndrome; yet, an approach to treatment remains unclear. Prior studies have demonstrated the efficacy of complementary and alternative medicine (CAM) for the treatment of acute COVID-19 infections, but little data exist regarding the potential use of CAM in the treatment of Long COVID. Objectives: Identify CAM approaches useful in treating the GI symptoms of Long COVID. Design: A systematic review of studies reporting on the use of CAM for the treatment of GI symptoms of Long COVID was performed. Data Sources and Methods: Five electronic databases were searched from January 2019 to November 2022. Studies describing the use of CAM to treat GI symptoms of Long COVID were included and assessed by two independent reviewers. Studies not reporting on GI symptoms or using CAM were excluded. Studies chosen for final review underwent quality and bias assessment using predetermined criteria. The extracted data were synthesized utilizing a framework derived from the National Center of Complementary and Integrative Health categories. Results: The initial search yielded 396 articles. After applying the eligibility criteria, a total of four studies (three case reports and one case series) were included for final review. Two studies used nutritional supplements and two studies used traditional Chinese medicine. Reductions in nausea, loss of appetite, diarrhea, acid reflux, epigastric pain, and bloating were reported. Conclusion: This is the first systematic review to explore the role of CAM in treating GI manifestations of Long COVID. The review identified four studies, all reporting reductions in the GI symptoms of Long COVID. Despite the positive studies included in this review, the overall search yielded few results, all of which were non-experimental. As the post-infectious sequelae of COVID-19 become better recognized in the wake of the pandemic, higher-quality clinical studies are needed.
A novel rapamycin cream formulation improves facial angiofibromas associated with tuberous sclerosis complex: a double-blind randomized placebo-controlled trial
Aitken, Phillip , Stanescu, Ioana , Boddington, Laura , Mahon, Caroline , Fogarasi, András , Liao, Yi‐Hua , Ivars, Marta , Trauner, Doris A. , DeRoos, Steven T., Nikolić, Miloš , Balážová, Patrícia , Price, Harper , Riney, Kate , Tollefson, Megha M. , Bauer, Derek, Pinková, Blanka, Atkinson, Hartley C., Moreno-Artero, Ester , Jancic, Jasna , Nikolic, Milos , Price, Harper N , Hadzsiev, Kinga , Stapleton, Stacie L. , Bauer, Derek

Mayo Clinic

British Journal of Dermatology | July 17, 2023 | Volume: 189 | Issue: 5 | Pages: 520-530

10.1093/bjd/ljad243 | PMID 37463422 Get It

Abstract Background Facial angiofibromas (FAs) are a major feature of tuberous sclerosis complex (TSC). Topical rapamycin can successfully treat FAs. A new stabilized cream formulation that protects rapamycin from oxidation has been developed in 0.5% and 1% concentrations. Objectives To assess the efficacy and safety of a novel, stabilized topical rapamycin cream formulation. Methods This multicentre double-blind randomized placebo-controlled dose–response phase II/III study with a parallel design included participants aged 6–65 years with FAs of mild or moderate severity according to the Investigator’s Global Assessment (IGA) scale. Participants were randomized to one of three treatment arms: topical rapamycin 0.5%, topical rapamycin 1% or placebo. Treatment was applied once daily for 26 weeks. Safety and efficacy measures were assessed at days 14, 56, 98, 140 and 182. The primary endpoint was the percentage of participants achieving IGA scores of ‘clear’ or ‘almost clear’ after 26 weeks of treatment. Secondary measures included Facial Angiofibroma Severity Index (FASI) and participant- and clinician-reported percentage-based improvement. Safety measures included the incidence of treatment-emergent adverse events and blood rapamycin concentration changes over time. Results Participants (n = 107) were randomized to receive either rapamycin 1% (n = 33), rapamycin 0.5% (n = 36) or placebo (n = 38). All treated participants were included in the final analysis. The percentage of participants with a two-grade IGA improvement was greater in the rapamycin 0.5% treatment group (11%) and rapamycin 1% group (9%) than in the placebo group (5%). However, this was not statistically significant [rapamycin 0.5%: odds ratio (OR) 1.71, 95% confidence interval (CI) 0.36–8.18 (P = 0.50); rapamycin 1%: OR 1.68, 95% CI 0.33–8.40 (P = 0.53)]. There was a statistically significant difference in the proportion of participants treated with rapamycin cream that achieved at least a one-grade improvement in IGA [rapamycin 0.5%: 56% (OR 4.73, 95% CI 1.59–14.10; P = 0.005); rapamycin 1%: 61% (OR 5.14, 95% CI 1.70–15.57; P = 0.004); placebo: 24%]. Skin adverse reactions were more common in patients following rapamycin application (64%) vs. placebo (29%). Conclusions Both rapamycin cream formulations (0.5% and 1%) were well tolerated, and either strength could lead to clinical benefit in the treatment of FA.